Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.

Status: Not covered — watchlist drug

Will CagriSema Be Covered by the CMS BALANCE Model?

By The RX Index Editorial Team — Last verified: June 1, 2026.

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers.

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

Coverage conclusions come from CMS, the FDA, Novo Nordisk, and the sources cited below — affiliate relationships never change them. Not medical advice.

No — CagriSema is not covered

CagriSema is not covered by the CMS BALANCE Model or the Medicare GLP-1 Bridge as of June 1, 2026. The BALANCE drug list right now includes all formulations of Foundayo, Mounjaro, Ozempic, Rybelsus, and Wegovy, plus the KwikPen form of Zepbound — CagriSema is on none of them. CagriSema is still investigational (not yet approved). Novo Nordisk filed its application December 18, 2025, and a decision is expected in late 2026. Until the FDA approves it, there is nothing for CMS to cover.

Coverage status at a glance

Your situation	Is CagriSema covered?	What this means for you
Medicare (BALANCE Model)	No	Not on the BALANCE drug list.
Medicare GLP-1 Bridge	No	Not on the Bridge list -- but three other GLP-1s are, starting July 1, 2026.
Medicaid (BALANCE)	No	Depends on your state, and CagriSema isn't listed anywhere yet.
Private insurance	No	Can't be covered until the FDA approves it.
Cash-pay / compounded	No	The FDA says cagrilintide can't be legally compounded. Don't buy it.

Not sure which path fits your situation? Take our free 60-second GLP-1 path quiz. It sorts you by coverage type — Medicare Bridge, Medicaid, private insurance, or cash-pay — and tells you your most likely next step.

Take the free GLP-1 path quiz →

Is CagriSema covered by the CMS BALANCE Model?

No. CagriSema is not on the CMS BALANCE Model drug list as of June 1, 2026. The BALANCE list currently includes all formulations of Foundayo, Mounjaro, Ozempic, Rybelsus, and Wegovy, plus the KwikPen form of Zepbound. CagriSema is not FDA-approved and is not on that list.

What is BALANCE? BALANCE stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth. It's a voluntary program from the CMS Innovation Center — the part of Medicare and Medicaid that tests new ways to pay for care. CMS launched it in December 2025. For the first time it sets aside the rule that normally blocks Medicare from paying for weight-loss drugs, negotiating a lower price on a set list of drugs.

BALANCE has two moving pieces on different timelines

▶The Medicaid side can start as early as May 2026 — but only in states that choose to join.
▶The Medicare Part D side was scheduled to begin in January 2027 — but it is not launching on schedule (more below).

Either way, CagriSema isn't in the program. To be in the program, a drug first has to be approved by the FDA and negotiated onto the list. CagriSema isn't there yet.

Why isn't CagriSema covered yet? The four gates it has to pass

CagriSema isn't covered because it hasn't cleared the gates every drug must pass to reach a CMS list. Think of coverage like four locked doors. CagriSema is standing at the first one.

Gate 1FDA approvalNot yet

Novo Nordisk submitted its New Drug Application on December 18, 2025. The FDA review is expected during 2026; a decision could come in late 2026 under a standard review timeline, though no exact date has been confirmed. Until the FDA says yes, there is no approved CagriSema product for CMS to cover.

Track in our CagriSema FDA approval status guide.

Gate 2CMS drug-class rulesPlausible

CMS says a qualifying product must work as -- or include -- a GLP-1, GIP, or glucagon receptor agonist, and show an average weight reduction of at least 9.5% in a clinical trial. CagriSema's semaglutide component is a GLP-1, and the REDEFINE 1 trial showed 22.7% weight loss. The amylin part (cagrilintide) isn't in CMS's named classes -- but the semaglutide component may be enough to qualify. Not confirmed.

Gate 3A negotiated spot on the listNot done

CMS doesn't auto-add new drugs. CMS and the drugmaker have to agree on price and terms. That negotiation already happened in early 2026 -- without CagriSema. CMS has said the model may need renewed negotiations because of the fast-moving drug landscape. That's a door that can open -- not one that opens by itself.

Gate 4Your own eligibilitySeparate question

Even when a drug is covered, you still have to qualify -- with a prior authorization (your doctor's request to the program), a qualifying BMI, and a qualifying diagnosis. We detail those exact rules further below.

CagriSema CMS Coverage Readiness Tracker

Verified June 1, 2026

Coverage gate	CagriSema status	Why it matters	Verified source
FDA approval for weight management	Not yet	NDA filed Dec 18, 2025; review expected in 2026. Investigational.	Novo Nordisk
Fits CMS drug-class rules	Plausible via its GLP-1 part	Contains semaglutide (a GLP-1); amylin isn't a named CMS class.	CMS BALANCE
Meets CMS weight-loss bar (~9.5%)	Yes, on trial data	22.7% loss in REDEFINE 1 -- but no FDA-approved dose yet.	CMS BALANCE / Novo
On the BALANCE drug list	No	List: Foundayo, Mounjaro, Ozempic, Rybelsus, Wegovy, Zepbound KwikPen.	KFF; CMS
On the Medicare GLP-1 Bridge list	No	Bridge list: Foundayo, Wegovy (injection + pill), Zepbound KwikPen.	CMS
Price negotiated with CMS	No	Negotiation happened in early 2026, before CagriSema was submitted.	American Action Forum
Your own eligibility confirmed	N/A for now	Moot until above gates are passed.	CMS eligibility rules

The honest read: Nobody can promise you CagriSema will end up covered by CMS. If another page tells you “CagriSema will be covered by Medicare,” they're skipping the approval-and-negotiation steps that haven't happened. It's a watchlist drug, not a covered drug — so you can plan around what's real instead of a maybe.

Will CagriSema be covered by CMS BALANCE later? The Foundayo precedent

For CagriSema to be covered by CMS, the FDA would first have to approve it, and then CMS would have to negotiate it onto a covered list. There is a recent precedent for exactly this: CMS added Foundayo to the Medicare GLP-1 Bridge after the FDA approved it. That precedent is the clearest signal we have of the path CagriSema would follow — but the timing is tight.

The realistic roadmap for CagriSema

The FDA approves CagriSema for weight management (review expected in 2026, a decision possibly late in the year).
CMS and Novo Nordisk negotiate price and terms.
CMS updates a covered list to add it.

The clock is the problem

→A CagriSema FDA decision is, at best, expected around late 2026.
→The Medicare GLP-1 Bridge — the Medicare pathway that 's actually scheduled to run — ends December 31, 2027.
→The longer-term BALANCE program for Medicare Part D did not launch on schedule (next section explains why).

Even in the best case — fast approval, fast negotiation — CagriSema would be arriving late to a program that's already winding down, with no confirmed long-term Medicare home behind it. “Covered by CMS” for CagriSema is, at best, a narrow and uncertain window — not a sure thing to wait on if you have a covered option you can use now.

Is CagriSema in the Medicare GLP-1 Bridge?

No. The Medicare GLP-1 Bridge is scheduled to cover Foundayo, Wegovy (injection and pill), and the Zepbound KwikPen — not CagriSema. The Bridge is a temporary Medicare program that will give eligible Part D members access to certain weight-loss GLP-1s for a flat $50 monthly copay, from July 1, 2026 through December 31, 2027.

Bridge details worth knowing

✓CMS will provide eligible Medicare beneficiaries access to certain GLP-1s for $50 per month from July 1, 2026 through December 31, 2027. (End date was extended from the original December 2026.)
✓You pay the same $50 every month, no matter where you are in your drug-plan year.
✓The Bridge runs outside your normal Part D benefit. Your Part D plan doesn't have to opt in for you to use it. CMS named Humana as the central processor that handles the paperwork and pays pharmacies.
⚠The $50 does not count toward your true out-of-pocket costs, so it won't push you toward your yearly cap.

Can my doctor submit the Bridge prior authorization before July 1, 2026?

No. CMS says prior authorization requests will not be accepted or processed before July 1, 2026. CMS also says beneficiaries don't need to register or take any action right now, and that it will post the prior authorization process — including a fax form — in June 2026. The weeks before July are for getting your paperwork ready, not for expecting an approved Bridge claim.

What's the difference between CMS BALANCE and the Medicare GLP-1 Bridge?

BALANCE is the broader, longer-term CMS model for covering GLP-1s across Medicaid and (eventually) Medicare Part D. The Medicare GLP-1 Bridge is a separate, short-term program scheduled to give eligible Part D members $50-a-month access to a few GLP-1s from July 2026 through December 2027. They are not the same thing, they have different drug lists, and they're on different clocks.

Feature	CMS BALANCE Model	Medicare GLP-1 Bridge
What it is	Longer-term model for GLP-1 access + lifestyle support	Short-term Medicare demonstration
Medicare timing	Was set for Jan 2027 -- not launching on schedule	Scheduled July 1, 2026 -- Dec 31, 2027
Medicaid timing	States can join May 2026 -- Jan 1, 2027	Not a Medicaid program
Who's covered	Depends on state (Medicaid) / plan (Medicare)	Eligible Part D members nationwide
Drug list	Foundayo, Mounjaro, Ozempic, Rybelsus, Wegovy, Zepbound KwikPen	Foundayo, Wegovy (injection + pill), Zepbound KwikPen
Monthly copay	Varies (negotiated, $245 net price baseline)	$50 flat -- does not count toward TrOOP

Why everyone's confused: The Medicare Part D part of BALANCE has been indefinitely delayed. It was supposed to begin in January 2027, but it only moved forward if at least 80% of Part D members were in participating plans — and that threshold wasn't met. So for Medicare, the Bridge is what you've got. And it has an expiration date.

Which GLP-1 drugs are scheduled for the Medicare GLP-1 Bridge?

If you're enrolled in an eligible Part D plan type and you qualify, CMS says you may access one of three FDA-approved weight-loss GLP-1s for $50 a month through the Bridge beginning July 1, 2026: Foundayo, Wegovy, or the Zepbound KwikPen. CagriSema is not one of them.

Drug	On the Bridge?	Included formulation	Excluded / note
Foundayo	Yes	All formulations (oral pill)	Added after FDA approval
Wegovy	Yes	Injection and tablets	All formulations included
Zepbound	Yes	KwikPen only	Single-dose vial and single-dose pen excluded
Ozempic / Mounjaro	No (for weight loss)	Covered by standard Part D only for type 2 diabetes	Weight-loss indication not covered via Bridge
CagriSema	No	Not FDA-approved	—
Compounded GLP-1s	No Bridge listing	Not listed as eligible Bridge drugs	—

If you came here because CagriSema sounded like the answer, this is the good news hiding under the disappointing headline: there's a real, affordable, FDA-approved option you may be able to start this summer — not a someday drug.

Who qualifies for the $50 Medicare GLP-1 Bridge?

To qualify for the Bridge, you must be enrolled in an eligible Medicare Part D plan type and meet one of three BMI-and-diagnosis pathways, measured at the time you first started GLP-1 therapy. Your doctor confirms this in a prior authorization request. If CagriSema were ever added, these are the rules to expect unless CMS updates the Bridge criteria.

Pathway	BMI requirement	Additional conditions
Pathway 1	BMI 35 or higher	Age 18+. No other diagnosis needed.
Pathway 2	BMI 30 or higher	Age 18+, plus a diagnosis of heart failure with preserved ejection fraction, uncontrolled high blood pressure (on two or more BP medicines), or chronic kidney disease stage 3a or higher.
Pathway 3	BMI 27 or higher	Age 18+, plus a diagnosis of prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.

Two things people get wrong — read these twice

1. The BMI is measured at the start of treatment, not today. CMS gives this exact example: if you started a GLP-1 in September 2024 with a BMI of 37 and you're down to a BMI of 34 by July 2026, your provider should attest that you met the BMI-35 rule when you started. Losing weight does not disqualify you — that would punish success.

2. There's also a lifestyle requirement. The medicine has to be paired with structured nutrition and physical activity, in line with the FDA-approved label. It's how the program is designed to work.

What Medicare Part D plan types qualify? You need an eligible Part D plan type — not just Medicare in general. CMS lists standalone Prescription Drug Plans (PDPs) and Medicare Advantage plans with drug coverage (HMOs, HMOPOS, and local/regional PPOs) as eligible, along with Special Needs Plans, employer/union group waiver plans, the LI NET program, and dually-eligible beneficiaries. Some plan types are not eligible unless you're also enrolled in a standalone PDP — including private fee-for-service plans, section 1876 cost contract plans, PACE organizations, and fallback plans. See our how to qualify for the Medicare GLP-1 Bridge guide for the plan-type details.

What diagnoses make the Bridge the wrong path? Type 2 diabetes, established cardiovascular disease (with obesity or overweight), and moderate-to-severe sleep apnea (with obesity) are Part-D-coverable indications. If your prescription is for one of those, it runs through your regular Part D benefit — your normal copay applies, and unlike the Bridge, that copay counts toward your $2,100 yearly out-of-pocket cap. So if you have a GLP-1-treatable condition beyond weight alone, check your regular Part D coverage first; it may be the better deal.

Free Prescriber Checklist Builder

Build my free prescriber question checklist

Two quick questions. Get a personalized list of exactly what to confirm with your doctor before July 1, 2026. Not medical advice.

What type of health coverage do you have?

Will CagriSema cost $50 if CMS adds it later?

No one can say that today, and it would be wrong to promise it. The $50 figure is the copay for the drugs currently scheduled in the Medicare GLP-1 Bridge. Behind that copay, drugmakers agreed to a $245 net price per 30-day supply for the Medicare program's drugs. A future, unlisted drug like CagriSema would have no negotiated price until CMS and Novo Nordisk actually struck a deal.

The fine print on the $50: Because the Bridge runs outside the normal Part D benefit, the $50 copay won't count toward your Part D deductible or your yearly out-of-pocket cap. It's a flat, predictable price — but it doesn't move you closer to your plan's spending limits.

The “$50 GLP-1 for Medicare” headline is real. It's also narrower than it looks: it applies to specific drugs, for eligible people, for a limited time. If you've been assuming every GLP-1 — including a future CagriSema — would automatically be $50, that's the assumption to let go of.

Could Medicaid cover CagriSema under BALANCE before Medicare does?

Possibly, eventually — but not today, and it depends entirely on your state. Medicaid coverage under BALANCE can start as early as May 2026, but only in states that choose to participate. CagriSema isn't FDA-approved, so no state Medicaid program covers it today.

Medicaid is run state by state, and coverage of weight-loss drugs is uneven — and getting tighter. Only 13 states covered GLP-1s for obesity as of January 2026, down from 16 the year before. California's Medi-Cal stopped covering GLP-1s for weight loss for members 21 and older as of January 1, 2026. So even after CagriSema is approved, whether your state's Medicaid program would add it is a separate question with a state-specific answer.

What to check	Where to look	What it means for CagriSema
Does my state participate in BALANCE?	Your state Medicaid site / bulletins	Only matters once CagriSema is approved and listed
Does my state cover obesity GLP-1s today?	Your state's drug list / PA rules	No CagriSema coverage today regardless
Did my state recently drop GLP-1 obesity coverage?	Recent Medicaid pharmacy alerts	Approval alone may not create access

For the current state-by-state picture, see our GLP-1 Medicaid coverage by state guide.

Can you get compounded CagriSema or cagrilintide while you wait?

⚠ No — and this matters more than any coverage tip on this page

The FDA states that cagrilintide cannot be used in compounding under federal law, and it has not been found safe and effective for any condition. Any “compounded CagriSema,” “cagrilintide,” or “research peptide” offer you see online is not a legitimate or legal way to get this drug early. The FDA has issued warning letters to companies selling unapproved peptides — including cagrilintide and retatrutide — for weight loss.

How to read gray-market listing language

What the listing says	What it actually means
"Compounded CagriSema"	Not a lawful CagriSema shortcut
"Cagrilintide research peptide"	Not an FDA-approved drug product
"Not for human use" / "research only"	Do not treat this as a patient medication
"No prescription required"	Not a legitimate medical path

What to do instead:

Watch the FDA decision. That's the real starting gun, expected during 2026.
Ask your clinician about an FDA-approved GLP-1 you can actually get — Wegovy, Zepbound, or Foundayo.
Fill prescriptions at a licensed pharmacy, with a prescription from a licensed provider.

Should you wait for CagriSema or use a covered option now?

For most people asking about CMS coverage, the practical move is to check what's available first, then keep CagriSema on your radar with your doctor. Waiting on CagriSema makes sense only if your clinician believes no current option fits you and you're comfortable with an uncertain approval-and-coverage timeline.

If you're on Medicare Part D

Don't wait to check your coverage path. See whether you fit one of the three Bridge pathways above, confirm you're in an eligible Part D plan type, and ask your prescriber about timing once the Bridge opens July 1, 2026. Gather your BMI-at-start documentation now — it's the thing most likely to slow you down.

If you're on Medicaid

Check your own state's current GLP-1 coverage — it varies a lot. Watch your state's Medicaid pharmacy updates. Don't assume another state's rules apply to you. See our GLP-1 Medicaid coverage by state guide.

If you have private (non-Medicare) insurance

CagriSema still isn't available — but you may have covered GLP-1 options now. If you want to see what your plan covers for an FDA-approved GLP-1, Ro offers a free GLP-1 Insurance Coverage Checker. Ro says the checker contacts your insurer to prepare a personalized coverage report.

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

Ro's free checker…	…does it apply here?
Helps with private insurance for FDA-approved GLP-1s	Yes
Enrolls you in the Medicare GLP-1 Bridge	No
Makes CagriSema available	No
Replaces your plan or prescriber	No

Check your private-insurance coverage with Ro's free GLP-1 checker →

If you're paying cash

CagriSema isn't sold commercially, and compounded cagrilintide isn't a legal or safe option (see above). The honest next step is to compare FDA-approved options and their real cash prices. See our CagriSema vs Wegovy HD comparison for what's available now.

What we actually verified

This page's answer rests on facts that can change — CMS drug lists, the FDA decision, program dates, and state Medicaid rules. We verified each item below directly against CMS, the FDA, KFF, and Novo Nordisk on June 1, 2026.

What we checked	What we found	Source
CagriSema FDA status	NDA filed Dec 18, 2025; investigational; review expected in 2026	Novo Nordisk; Drugs.com
On the BALANCE drug list	Not listed (list: Foundayo, Mounjaro, Ozempic, Rybelsus, Wegovy, Zepbound KwikPen)	KFF; CMS
On the Medicare GLP-1 Bridge	Not listed (list: Foundayo, Wegovy injection + pill, Zepbound KwikPen)	CMS
Bridge dates and copay	July 1, 2026 -- Dec 31, 2027; $50/month	CMS
Bridge eligibility	BMI 35; or 30+ with condition; or 27+ with condition; PA required; eligible plan types only	CMS
Prior authorization timing	Not accepted or processed before July 1, 2026	CMS
BALANCE Medicare Part D status	Did not launch on schedule; indefinitely delayed	KFF
Compounded cagrilintide	Cannot be used in compounding; not found safe/effective	FDA

Frequently asked questions

Quick answers to the questions people search most about CagriSema and CMS coverage.

Is CagriSema covered by the CMS BALANCE Model?

No. The current BALANCE drug list includes all formulations of Foundayo, Mounjaro, Ozempic, Rybelsus, and Wegovy, plus the Zepbound KwikPen. CagriSema is not on the list because it is not yet FDA-approved.

Is CagriSema covered by the Medicare GLP-1 Bridge?

No. The Bridge is scheduled to cover Foundayo, Wegovy injection and tablets, and the Zepbound KwikPen beginning July 1, 2026 for eligible beneficiaries. CagriSema is not included.

Is CagriSema FDA-approved?

No. Novo Nordisk submitted its FDA application on December 18, 2025, and CagriSema remains investigational. The FDA's review is expected during 2026.

Could CagriSema be added to CMS coverage later?

Possibly. CMS has said it may renew negotiations as new drugs enter the market, and it already added Foundayo to the Bridge after FDA approval. But it would require FDA approval first, then a CMS negotiation -- neither of which has happened.

What drugs are in the CMS BALANCE Model?

All formulations of Foundayo, Mounjaro, Ozempic, Rybelsus, and Wegovy, plus the KwikPen formulation of Zepbound.

What drugs are scheduled for the Medicare GLP-1 Bridge?

Foundayo, Wegovy injection and pill, and the Zepbound KwikPen, for weight management, for eligible Part D members, beginning July 1, 2026.

How much do Medicare GLP-1 Bridge drugs cost?

A flat $50 copay per monthly supply for eligible people. That $50 does not count toward your Part D deductible or your yearly out-of-pocket cap.

Who qualifies for the Medicare GLP-1 Bridge?

Members of an eligible Part D plan type who meet one of three pathways at the time they started therapy: BMI 35 or higher; BMI 30 or higher with certain heart or kidney conditions; or BMI 27 or higher with prediabetes or a history of heart attack, stroke, or peripheral artery disease. A doctor submits a prior authorization.

Can my doctor submit a Bridge prior authorization before July 1?

No. CMS says prior authorization requests will not be accepted or processed before July 1, 2026. June is for getting documentation ready.

Can I get compounded CagriSema?

No. The FDA says cagrilintide cannot be used in compounding under federal law and has not been found safe and effective for any condition. Avoid any product offering it.

Should I wait for CagriSema?

Not just for coverage reasons. It is not FDA-approved or CMS-listed, so the practical move is to check currently available options and track CagriSema with your clinician for future updates.

Still not sure which GLP-1 program is right for you?

Our free 60-second quiz matches you to the right path based on your coverage type, situation, and goals.

Take the free 60-second matching quiz →

Related guides

Sources

CMS — BALANCE Model
CMS — Medicare GLP-1 Bridge
CMS — Information for Medicare Beneficiaries (eligibility, PA timing, $245 net price, TrOOP)
CMS — Information for Providers (plan types, central processor, extension)
KFF — What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid (drug list, $245, Part D delay, Medicaid)
FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (cagrilintide compounding)
Novo Nordisk — CagriSema NDA submission (Dec 18, 2025)
Drugs.com — CagriSema FDA Approval Status
CMS BALANCE drug eligibility criteria: cms.gov/priorities/innovation/innovation-models/balance

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We don't provide medical care or coverage decisions. Always confirm current coverage at CMS.gov and with your plan, and talk to a licensed provider about your treatment.

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

See our affiliate disclosure for details. Last verified June 1, 2026.